Johnson & Johnson (JNJ) Latest Stock News & Headlines
Get the latest Johnson & Johnson (JNJ) stock news and headlines to help you in your trading and investing decisions.
Latest news - Johnson & Johnson
A collection of stories that highlight the way Johnson & Johnson is making an impact in the lives of its consumers, and the latest press releases from the company.
J&J Reports Strong Earnings, Grapples with Ongoing Legal …
Oct 15, 2024 · Johnson & Johnson's (NYSE:JNJ) latest earnings reveal a company navigating both growth and legal hurdles. With a 5.2% sales increase, bringing in $22.5 billion, J&J continues to outperform...
Johnson & Johnson's Q3 Earnings: Revenue And EPS Beat On …
Oct 15, 2024 · On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter adjusted EPS of $2.42, down 9.0% year-over-year, beating the consensus of $2.21. The pharmaceutical giant reported sales of...
Johnson & Johnson Reports Q3 2024 Results | Johnson & Johnson
Oct 15, 2024 · 2024 Third-Quarter reported sales growth of 5.2% to $22.5 Billion with operational growth of 6.3%* and adjusted operational growth of 5.4%*. 2024 Third-Quarter Earnings per share (EPS) of $1.11 decreasing by 34.3% due to a one-time special charge and acquired IPR&D. Adjusted EPS of $2.42 decreasing by 9.0%* with acquired IPR&D impacting results ...
Johnson & Johnson MedTech Receives FDA Approval for the …
Irvine, CA – November 7, 2024 – Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug refractory paroxysmal Atrial Fibrillation (AFib).. The VARIPULSE™ Platform is designed to enable AFib treatment with a single device that combines PFA therapy ...
Johnson & Johnson Announces Plans to Accelerate Innovation, …
Nov 12, 2021 · The new Johnson & Johnson would continue to play a leading role in advancing the industry forward by creating novel solutions, bringing together treatments spanning therapeutics, robotics, artificial intelligence and more, to change the way diseases are prevented, intercepted and eventually cured.
Cancer drug sales lift J&J past Wall Street expectations
Oct 15, 2024 · Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.
Johnson & Johnson to Acquire Ambrx, Advancing Next
Jan 8, 2024 · NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug ...
Johnson & Johnson (JNJ) Stock Price & News - Google Finance
Get the latest Johnson & Johnson (JNJ) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.